Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ATF1 | P18846 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | GLP1R | P43220 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24843666 | 0.82 | UHRF1 (0.35) | KDM4EUHRF1 | |
| SCHEMBL23099869 | 0.80 | CCR1 (0.34) | ATF1NFKB1GLP1R | |
| SCHEMBL20118471 | 0.80 | PLAU (0.42) | CYP1A2CYP2C19ATF1NFKB1ALDH1A1 | |
| SCHEMBL24843484 | 0.78 | UHRF1 (0.33) | KDM4EUHRF1 | |
| SCHEMBL23148014 | 0.77 | KDM4E (0.30) | KDM4EALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL20496003 | 0.76 | UHRF1 (0.34) | KDM4EUHRF1POLBSMN1; SMN2 | |
| SCHEMBL24843658 | 0.74 | KDM4E (0.34) | KDM4EUHRF1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL23148190 | 0.73 | KDM4E (0.33) | KDM4EUHRF1 | |
| SCHEMBL31539741 | 0.73 | GLP1R (0.38) | KDM4ECYP1A2CYP3A4CYP2C19ATF1 | |
| SCHEMBL29721726 | 0.73 | KDM4E (0.33) | KDM4EUHRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | AZI2, AADAC, TPMT | KDM4E 1203/4885UHRF1 2896/4885CYP1A2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.